Ocuphire Pharma Inc (REXN)

NYSE
1.810
0.000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    1.720/1.920
  • Day's Range:
    1.720 - 1.920

REXN Overview

Prev. Close
1.87
Day's Range
1.72-1.92
Revenue
-
Open
1.85
52 wk Range
1.71-2.84
EPS
-5.12
Volume
0
Market Cap
7.27M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
384,046
P/E Ratio
-
Beta
0.82
1-Year Change
-35.59%
Shares Outstanding
4,019,141
Next Earnings Date
-
What is your sentiment on Ocuphire Pharma Inc?
or
Market is currently closed. Voting is open during market hours.

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellSellStrong SellStrong Sell
Technical IndicatorsBuyStrong SellStrong SellStrong SellStrong Sell
SummaryNeutralStrong SellStrong SellStrong SellStrong Sell

Ocuphire Pharma Inc Company Profile

Ocuphire Pharma Inc Company Profile

Employees
5

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.

Read More
  • BLIN is next MRIN
    0
    • I like $12. Holding until then at least. Good company.
      0
      • Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint
        1
        • Any target price?
          0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.